Table 5.

Comparison of Agents for Treatment of Drug-Resistance Gram-Negative Infections

	In Vitro Activity
	Enterobacterales
Agent	Ambler Class A	Ambler Class B	Ambler Class D	Pseudomonas aeruginosa	Acinetobacter baumannii	Stenotrophomonas maltophilia	US Food and Drug Administration–Approved Indications	Daily Cost for Normal Renal Function
Cefiderocol	Yes	Yes	Partial	Yes	Yes	Yes	cUTI/AP, HABP/VABP	$1320.00
Ceftazidime-avibactam	Yes	No	Yes	Yes	No	No	cUTI/AP, cIAI, HABP/VABP	$1291.71
Ceftolozane-tazobactam	No	No	No	Yes	No	No	cUTI/AP, cIAI	$450.78
Meropenem-vaborbactam	Yes	No	No	Yes	No	No	cUTI/AP	$1283.04
Imipenem-cilastatin-relebactam	Yes	No	No	Yes	No	No	cUTI/AP, cIAI	$1322.56

Dosing: Cefiderocol: 2 g intravenous (IV) every 8 hours. Ceftazidime-avibactam: 2.5 g (ceftazidime 2 g/avibactam 0.5 g) IV every 8 hours. Ceftolozane-tazobactam: 1.5 g (ceftolozane 1 g/tazobactam 0.5 g) IV every 8 hours. Meropenem-vaborbactam: 4 g (meropenem 2 g/vaborbactam 2 g) IV every 8 hours. Imipenem-cilastatin-relebactam: 1.25 g (imipenem 500 mg/cilastatin 500 mg/relebactam 250 mg) IV every 6 hours.

Abbreviations: AP, acute pyelonephritis; cIAI, complicated intraabdominal infection; cUTI, complicated urinary tract infection; HABP, hospital-acquired bacterial pneumonia; VABP, ventilator-associated bacterial pneumonia.